 |
Companies | Products |
|
|
Products | |
Diseases | |
Trials |  |
News |  |
- In vitro characterization of a dual antagonistic anti-LILRB2/LILRB4 monoclonal antibody (Section 41) - Mar 5, 2024 - Abstract #AACR2024AACR_7740;
We have identified a dual anti-LILRB2/LILRB4 antagonist. Targeting MDSCs with this antibody offers great promise for immunotherapy for cancer as well as its immense potential for synergy with PD-1 blockade.
- MK-4830 / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
Phase 1 study of the anti-immunoglobulin-like transcript 4 (ILT4) monoclonal antibody MK-4830 plus pembrolizumab in patients with previously untreated advanced head and neck squamous cell carcinoma (HNSCC) or non-small cell lung cancer (NSCLC) (Section 48) - Mar 5, 2024 - Abstract #AACR2024AACR_5185;
Targeting MDSCs with this antibody offers great promise for immunotherapy for cancer as well as its immense potential for synergy with PD-1 blockade. Abstract is embargoed at this time.
- LAE111 / Laekna Therap
Preclinical characterization of LAE111, a potent anti-LILRB1/LILRB2 antagonist bispecific antibody (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_922;
Abstract is embargoed at this time. Lead bispecific antibodies were characterized in a panel of functional assays together with the competitor